Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
AstraZeneca's suspension of global trials of its coronavirus vaccine dubbed AZD1222 triggered a 2 percent drop in its shares in London and a 12 plunge in the stock price of its Indian unit, AstraZeneca Pharma India Ltd.
The company is developing the AZD1222 vaccine with the University of Oxford.
The suspension, which dimmed the company's prospect of an early rollout, was necessary to review safety data after an unexplained illness in a participant.
AstraZeneca said that the suspension was routine every time there is a potentially unexplained illness in the trials.
The company is working to expedite the review to minimize any potential impact on the trial timeline.
The decision on restarting the trial will be taken by the medical regulator, the MHRA, that would take only days.
According to a New York Times report, citing a person familiar with the situation, the UK-based participant was found to have transverse myelitis, an inflammation that affects the spinal cord and is often sparked by viral infections.
Whether the condition was directly linked to AZD1222 remains unclear.
The AZD1222 has been described by the World Health Organization (WHO) as probably the world’s leading and the most advanced vaccine.
The vaccine is in late-stage clinical trials in the US, the UK, Brazil, and South Africa.
Additional trials are planned in Russia and Japan, targetting up to 50,000 participants globally.
The participant's reaction to AZD1222 has impacted clinical trials by other vaccine makers, which are on the lookout for similar reactions.
